Shares of less-lethal weapons manufacturer Byrna Technologies <a href="https://www.marketwatch.com/investing/stock/byrn?utm_source=in_materials">advanced</a> nearly 5% on Tuesday, December 17, to three-year highs. The company <a href="https://ir.byrna.com/news-events/press-releases/detail/208/byrna-increases-launcher-production-by-33-to-24000-units?utm_source=in_materials">announced</a> plans to boost U.S. production by 33% and open a new facility. Byrna also committed to exiting China and sourcing all the components for its flagship product domestically by the end of 2025, a decision accelerated by <strong>Donald Trump</strong>’s election as U.S. president.

Less-lethal weapons maker Byrna hits three-year high

Quotes on Sidus Space, a space services company, have quadrupled over the last two days. This week, the company plans to launch its second satellite. Ahead of this milestone, Sidus has <a href="https://investors.sidusspace.com/news-events/press-releases/detail/213/sidus-space-announces-14-million-private-placement?utm_source=in_materials">announced</a> a $14 million private placement, marking the fifth stock offering for the company this year.

Sidus Space quadruples in two days

Quotes on MAIA Biotechnology shares jumped 6.4% in U.S. premarket trading today, Tuesday, December 17, following a 10.0% surge the previous day. This came after the company announced that the FDA had <a href="https://ir.maiabiotech.com/news-events/press-releases/detail/120/maia-biotechnology-granted-fda-rare-pediatric-disease?utm_source=in_materials">granted</a> a special designation to its drug for pediatric brain tumors. The designation <a href="https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs?utm_source=in_materials">came with</a> a voucher that can be redeemed to receive priority review for another drug or sold for hundreds of millions of dollars.

MAIA soars after its cancer drug receives FDA 'rare pediatric disease' designation

Shares of easy-to-prepare food maker Mama’s Creations have <a href="https://www.marketwatch.com/investing/stock/mama/analystestimates?mod=mw_quote_tab&amp;utm_source=in_materials">plunged</a> more than 20% in premarket trading as of this writing today, Tuesday, December 17, following the <a href="https://ir.mamascreations.com/mamas-creations-reports-third-quarter-fiscal-2025-financial-results/?utm_source=in_materials">release</a> of earnings for the fiscal-2025 third quarter, which revealed year-over-year declines in net and gross profit amid revenue growth. Note that the financial report had been delayed after the company’s auditor was replaced.

Easy-to-prepare food manufacturer Mama’s Creations sinking after third-quarter earnings

The Royce Smaller-Companies Growth Fund has <a href="https://www.royceinvest.com/insights/2024/4Q24/three-small-cap-growth-stories-in-payments-processing?utm_source=in_materials">spotlighted</a> three small-cap growth stories in payments processing. These companies started out several years ago when the industry was built around equipment sales. However, they successfully shifted their business models to generate recurring revenue while remaining committed to innovation, noted Royce portfolio manager <strong>Chip Skinner</strong>.

Royce looks at three innovators in the payments processing industry

Simply Wall St <a href="https://finance.yahoo.com/news/now-opportunity-miller-industries-inc-134949655.html?utm_source=in_materials">believes</a> Miller Industries is worth 50% more than its current share price, having set the highest target price on Wall Street at $105.3 per share. Meanwhile, Freedom Broker downgraded the name in early December, dropping their "buy" recommendation.

Simply Wall St says Miller Industries is 50% undervalued 

Barchart.com has <a href="https://www.barchart.com/story/news/30007594/why-wall-street-rates-these-2-russell-2000-stocks-a-strong-buy?utm_source=in_materials">highlighted</a> two stocks from the Russell 2000 small-cap index that are rated as "strong buys" by Wall Street analysts and feature significant upside.

Barchart.com highlights two Wall Street 'strong buys' from the Russell 2000 

The small-cap company IN8bio promises to revolutionize oncology with cell therapies, including for the highly aggressive glioblastoma. While this treatment is a groundbreaking advancement that took place not long ago, its use remains limited. IN8bio seeks to change that.

How the small-cap IN8bio is revolutionizing cancer treatment

The Russell 2000 small-cap index is expected to have a better 2025 than the S&amp;P 500, its large-cap counterpart, <a href="https://www.cnbc.com/2024/12/11/bull-market-to-continue-with-small-caps-on-top-piper-sandler.html?utm_source=in_materials">according</a> to an analyst at the investment bank Piper Sandler. Such an outperformance usually takes place in the third year of a bull market, which will come in 2025.

Piper Sandler sees the Russell 2000 outperforming the S&amp;P 500 in 2025

Shares of Lightwave Logic, a development stage company developing electro-optic photonic devices, hit an <a href="https://www.nasdaq.com/market-activity/stocks/lwlg?utm_source=in_materials">all-time low</a> on Wednesday, December 11. The company <a href="https://www.pressviewer.com/ViewEmail.asp?b=2586&amp;id=330473&amp;p=2353004&amp;I=1456003-g9f8b7r4N7&amp;utm_source=in_materials">announced</a> a management overhaul to accelerate commercialization of and identify new applications for its products.

Lightwave Logic shares plunge to record low following management shake-up

On Wednesday, December 11, shares of Krispy Kreme, a doughnut shop and coffeehouse chain, dropped after the company reported operational disruptions caused by a cyberattack. Hackers compromised its online ordering system in the U.S., and it might take months to recover, <a href="https://www.ft.com/content/7732e6ed-c07e-4520-833e-b858ba9bd432?utm_source=in_materials&amp;utm_source=in_materials">according</a> to the . While Krispy Kreme expects insurance to cover part of the costs, it warned that the attack is likely to have a "material impact on the company’s business operations" until the issues are fully resolved.

Krispy Kreme slides on news of cyberattack

In a recent note, Zacks Small-Cap Research (Zacks SCR) laid out why it believes Lexaria Bioscience, a micro-cap company that is working on making popular weight-loss injections like Wegovy and Zepbound into pills using its patented technology, should be valued at $8 per share — 222% above the current market price. The company is set to begin a new phase of trials soon that may yield sufficient data to attract the attention of larger market players like Denmark’s Novo Nordisk, the maker of Wegovy, Zacks SCR notes.

Small caps